MARKET WIRETradingView • 1d ago
Eocene Ltd. Estimates – NASDAQ:EOCNTradingView report covering Eocene Ltd. (EOCN) market action, institutional positioning, and fundamental catalysts.
Why EOCN Stock dropped -7.54% Today — RQD Quant Desk Flash
$2.87 -7.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.83
Eocene Ltd. (EOCN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $3.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EOCN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Eocene Ltd. (NASDAQ: EOCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.87 (-7.54% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, EOCN ranks #664 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EOCN compare to ERNA and CMND in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOCN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, EOCN leads on earnings multiple (N/A) while EOCN leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EOCN?
▼
Per EOCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595353), Eocene Ltd. generated $7.8M in revenue (+0.7% YoY), -$10.3M in net income, and -$6.3M in free cash flow against $18.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.83 (-1.55%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EOCN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY EOCN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.16-2.8% Next Q
42
Q2 (-2Q)Grade E$3.07+0.3% Next Q
39
Q3 (-1Q)Grade E$3.08-6.8% Next Q
37
CurrentGrade E$2.87-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EOCN Turnaround Squeeze
While EOCN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.53) and Max Pain ($3.01) forces dealer call-delta covering toward $12.94.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EOCN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EOCN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EOCN Stock dropped -7.54% Today — RQD Quant Desk Flash
Eocene Ltd. (EOCN) dropped -7.54% to $2.87, trading at 5% of its 52-week range ($2.33 – $12.32). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($2.33 – $12.32) with RSI-14 at 44 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.87 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live EOCN Headlines & Catalysts
MARKET WIREYahoo Finance • 55d ago
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI InnovationYahoo Finance coverage on EOCN stock catalysts, institutional flow, and earnings outlook.
MARKET WIRETD Economics • 4d ago
The Weekly Bottom Line<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5iS3JheUxIbE9wdXkzWk1rUkxjT1p6VTJWeW1uMVpPY1hKYTMtNFF2Qzh1ck5JNTNKVGRSWXlBOWFta2xtZ2tVUTVhT0FlUmpqX1M2UngxLXRZZw?oc=5" target="_blank">The Weekly Bottom L
CATALYSTDeloitte • 15d ago
Private capital–fueled economic growth might be knocking on India’s doors soon<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPbVNEUF9teW9VSlNOTVBOOXNjbVkybkFnOTVDNkljbWpGTld4Z1BhS243VUhJcHJqMjh3UWJDRkQwYlhTam9fMzQwTTRuejFnMlJrUjNteUVmZE5LeUc4ODVPRHhFYVlQNGU4S3RwX1dKc01XTTB4VTR0STV
MARKET WIRERetail Insider • 8d ago
Retail Insider “Q3 2026 Luxury Report”: Flagship Investment Changes the Store Economics<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxORnJTMFFsYVpfNWw3cHJ0cFZ4a3RuYWxUZVNRZ3QyRXF2dVBpU29OVWR6cHVvUU5OcW1jQzVKbnMzVUdTdEM3Q2lxZFhRNHJJWFptWE1UR2Z4Vi1VTDBtYzM1MVo3RzRfUmZOdm5sY3gzajNrMmsxdWZoU2Z
RISK WATCHTraders Union • 14d ago
Capital Economics sees stocks falling further as bond outlook improves<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQNjlLb0pxUlBHYlFGZU1HdUl6dzdJSXc1dHZsYkY0bkIzQ0RLbl9uYTZfUkJSRlZmNEJGcVRlVVJxb0pWbHRjOVZLSFFNN3RYRENpSXEtUjYzVXp4bHNSQW1nOWx5QTZaT19YSUM5eVRkQ1VzdEtXTEtYT0l
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EOCN)
- ✓Walkthrough of EOCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EOCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.94%▼ DESCENDING CHANNEL
2026-11-03O $3.22H $3.22L $2.87C $2.87VOL 3.1K
RES: $4.60SUP: $1.90SMA50: $3.53SMA200: $4.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EOCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on EOCN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EOCN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EOCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EOCN)
Health Care Rank #664 of 1015
⚔️ ERNA vs EOCN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EOCN vs. ERNA, CMND, SXTP, ONCO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Eocene Ltd. (EOCN) ranks #664 by composite RQD confidence (34/100, grade E) and #973 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, EOCN leads on earnings valuation at N/A trailing P/E, while EOCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with EOCN at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EOCN
ACTIVE
Eocene Ltd. | E | 34/100 | — | — | -35.0% | -7.54% | $3.2M | Benchmark Subject |
| ERNA Ernexa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -1.01% | $3.2M | /erna-vs-eocn → |
| CMND Clearmind Medicine Inc. | D | 47/100 | — | — | — | -1.27% | $3.2M | /cmnd-vs-eocn → |
| SXTP 60 Degrees Pharmaceuticals Inc. | D- | 38/100 | — | 22.3% | -35.0% | -3.65% | $3.3M | /sxtp-vs-eocn → |
| ONCO Onconetix Inc. | E | 30/100 | — | 77.6% | -35.0% | -3.24% | $3.3M | /onco-vs-eocn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001595353 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eocene Ltd. (EOCN) reported GAAP revenue of $7.8M (+0.7% vs. FY2024 revenue of $7.8M , and -74.8% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-7.4% YoY). On the balance sheet, EOCN closed FY2025 with $18.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.8M | -$10.3M | -$6.3M | -$6.3M | $18.6M | — |
| FY2024 (FY) | 2024-12-31 | $7.8M | -$7.5M | -$5.9M | -$5.9M | $18.5M | — |
| FY2023 (FY) | 2023-12-31 | $31.1M | -$6.9M | -$6.1M | -$6.1M | — | — |
3. EOCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Eocene Ltd. (NASDAQ: EOCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.87 (-7.54% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, EOCN ranks #664 in composite RQD confidence.
How does EOCN compare to ERNA and CMND in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOCN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, EOCN leads on earnings multiple (N/A) while EOCN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EOCN?
Per EOCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595353), Eocene Ltd. generated $7.8M in revenue (+0.7% YoY), -$10.3M in net income, and -$6.3M in free cash flow against $18.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EOCN trading relative to its 50-day, 200-day, and 52-week technical levels?
EOCN last traded at $2.87 (-7.54% on volume of 9,811 shares), positioning the stock -18.70% below its 50-day simple moving average ($3.53) and -37.06% below its 200-day simple moving average ($4.56). Across its 52-week range of $2.33 to $12.32, EOCN sits at the 5.4% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.51 to $3.23).
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ SEC XBRL & RQD VERIFIED
EOCN — Eocene Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Eocene Ltd. (EOCN) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.87 (-7.54% 1D, market capitalization $3.2M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Eocene Ltd. (EOCN) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. — describes its products, customers, or specific revenue model.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eocene Ltd. (EOCN) reported $7.8M in annual revenue (up from $7.8M in FY2024, +0.7% YoY) and -$10.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.1M revenue, -$6.9M net income) through FY2025, EOCN scaled operating cash flow to -$6.3M and free cash flow to -$6.3M, backed by $18.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.33 – $12.32 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The supply chain is NONE, with no upstream or downstream dependencies and no sector correlations recorded. — identifies any 2nd-order bottlenecks. A prospective investor should note that the absence of mapped links means the source data cannot show how a pharmaceutical development or commercial milestone would propagate through suppliers or partners.
- Key Question #1: Can EOCN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $7.8M and free cash flow of -$6.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is EOCN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
EOCN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Eocene Ltd. (EOCN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Eocene Ltd. Estimates – NASDAQ:EOCN TradingView report covering Eocene Ltd. (EOCN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 55d ago
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation Yahoo Finance coverage on EOCN stock catalysts, institutional flow, and earnings outlook.
🟡 MARKET WIRE TD Economics • 4d ago
The Weekly Bottom Line <a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5iS3JheUxIbE9wdXkzWk1rUkxjT1p6VTJWeW1uMVpPY1hKYTMtNFF2Qzh1ck5JNTNKVGRSWXlBOWFta2xtZ2tVUTVhT0FlUmpqX1M2UngxLXRZZw?oc=5" target="_blank">The Weekly Bottom L
🟢 CATALYST Deloitte • 15d ago
Private capital–fueled economic growth might be knocking on India’s doors soon <a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPbVNEUF9teW9VSlNOTVBOOXNjbVkybkFnOTVDNkljbWpGTld4Z1BhS243VUhJcHJqMjh3UWJDRkQwYlhTam9fMzQwTTRuejFnMlJrUjNteUVmZE5LeUc4ODVPRHhFYVlQNGU4S3RwX1dKc01XTTB4VTR0STV
🟡 MARKET WIRE Retail Insider • 8d ago
Retail Insider “Q3 2026 Luxury Report”: Flagship Investment Changes the Store Economics <a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxORnJTMFFsYVpfNWw3cHJ0cFZ4a3RuYWxUZVNRZ3QyRXF2dVBpU29OVWR6cHVvUU5OcW1jQzVKbnMzVUdTdEM3Q2lxZFhRNHJJWFptWE1UR2Z4Vi1VTDBtYzM1MVo3RzRfUmZOdm5sY3gzajNrMmsxdWZoU2Z
🔴 RISK WATCH Traders Union • 14d ago
Capital Economics sees stocks falling further as bond outlook improves <a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQNjlLb0pxUlBHYlFGZU1HdUl6dzdJSXc1dHZsYkY0bkIzQ0RLbl9uYTZfUkJSRlZmNEJGcVRlVVJxb0pWbHRjOVZLSFFNN3RYRENpSXEtUjYzVXp4bHNSQW1nOWx5QTZaT19YSUM5eVRkQ1VzdEtXTEtYT0l
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EOCN Bull vs. Bear Conversation Board — What's Your Call at $2.87?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EOCN 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $3.66 (+18.1%)
📌 Pinned Debate The stock trades at a $3.4M market capitalization with a Beta of 1.0 and a 52-week low of $2.33 well below the 52-week high of $12.32,
Here is why I am bullish on EOCN here at $3.10: The stock trades at a $3.4M market capitalization with a Beta of 1.0 and a 52-week low of $2.33 well below the 52-week high of $12.32, leaving room for a rerating if cash generation improves.. Compare EOCN's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.94 are getting bought.
ArenaChamp_24 🐂 BULL
@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $2.63 (-15.2%)
Spot @ $3.10 Free cash flow was negative in every reported period, from -$6.1M in FY 2023 to -$6.3M in FY 2025, with ROIC at -35% and cash falling f
Free cash flow was negative in every reported period, from -$6.1M in FY 2023 to -$6.3M in FY 2025, with ROIC at -35% and cash falling from $4.7M to $4.0M.. Look at the math on EOCN: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $2.73 before getting long.